On Friday, Partnership Assurance Group was valued more than US$2.4 billion in its debut at the London Market.
Healthcare Health/Fitness
Healthcare companies spearhead Swiss stocks advance
The Swiss Market Index climbed as Novartis advanced studies on multiple sclerosis while Roche releases arthritis drug.
UPDATE: Elan Rejects Fresh Bid from Royalty
Elan rejects the newest bid from Royalty and seeks to look at other unsolicited interested parties.
AstraZeneca Acquires Pearl Therapeutics for US$1.15 Billion
AstraZeneca purchases Pearl Therapeutics for US$1.15 billion, making it the second firm in Britain to rebuild products through deal making.
Royalty Pharma Urges NY Federal Court to Proceed With Elan Bid
Royalty Pharma urged the federal court in New York to lift the temporary restraining order it has ordered for the Royalty-Elan bid.
Latest News
Royalty Pharma's bid was threatened to be dismissed after the takeover panel released rulings that the US based company could no longer revise the terms on its proposed deal.
Royalty Pharma extends deadline for Elan to respond to its unsolicited offer. The private equity firm that invests in royalty streams from pharmaceuticals, Royalty Pharma, had extended the deadline for Elan Corp to respond to its US$6.
Apollo Investment Corp. discusses a near deal to acquire MidCap for US$500 million. (Photo : Reuters)The image is the corporate logo of Apollo Global Management.
Bayer purchases Conceptus shares and becomes majority shareholder without need for shareholder vote due to right to top up the transaction.
Bill Gates leads investment of US$35 Billion for ResearchGate, a Berlin based network for scientists.
Cinven Ltd, KKR & Co LP and Warburg Pincus LLC are weighing deals to bid for PRA International, a clinical research group.
Cardio3 BioSciences is planning an IPO after a previous unsuccessful run. (Photo : Reuters)The image is the microscopic view of a stem cell sample. Cardio3 BioSciences, the heart drug specialist pharmaceutical firm from Belgium, is now in the midst of planning the stock market offer of its shares in the Brussels and Paris bourses.
Shire Plc (SHP) pulled off a settlement agreement with Teva Pharmaceutical Industries Ltd. (TEVA), enabling the later to manufacture cheap generic copies of Intuniv.
CVC Capital Partners set to do IPO of Matas shares. CVC Capital Partners Ltd, the European private equity firm, is deep in preparations to sell part of its stake in Matas, the drugstore chain, through an IPO.
